Biotech News

Nektar Therapeutics to Participate in Two Investor Conferences in November

Nektar Therapeutics (NKTR)Nektar TherapeuticsConference / presentation

SAN FRANCISCO, Nov. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in two upcoming investor conferences. UBS Global Biopharma Conference Format: Fireside Chat and 1x1 meetings Fireside Chat Date: Tuesday, November 17, 2026

Related news

Nektar Therapeutics

Immune-Regulatory Therapeutics Nektar Therapeutics develops biologic medicines that selectively modulate immune-cell pathways. Its current portfolio emphasizes regulatory T-cell biology for autoimmune and inflammatory diseases. Rezpegaldesleukin Rezpegaldesleukin is an IL-2 pathway agonist designed to expand and activate regulatory T...

Recent company news

Stock data

Close
32.54 USD
Market cap
1.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States